NEW YORK — A new drug-delivery system with an anti-microbial agent has been developed to treat Methicillin-resistant Staphylococcus aureus (MRSA) and is showing promising results in mice, according to the United Press International.
Researchers at Albert Einstein College of Medicine of Yeshiva University infected mice with MRSA and administered treatment with the drug delivery system that uses biocompatible nanoparticles that are smaller than a grain of pollen to produce controlled and sustained amounts of nitrous oxide gas, the story stated.
According to the story, nitrous oxide, which is produced by many cells throughout the body, has several important biological functions, including killing bacteria, but its therapeutic potential has been difficult to harness.
The wounds of mice treated topically with nitrous oxide-containing nanoparticles improved significantly and had lower bacterial counts when compared to the control mice that received nitrous oxide-void nanoparticles or no treatment, the story noted.
Dr. Joel Friedman of Albert Einstein said: "The problem is that nitric oxide is very short-lived and, until now, methods to deliver it to targeted tissues in the proper dosages have proven elusive."
The results of the study were published online in the Journal of Investigative Dermatology, the story added.
Click here to read the complete article.
For related information, click here.